Sally Bridget Lawlor
CIK: 0002084407
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Quoin Pharmaceuticals, Ltd.
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- Aug 31, 2026QNRX
Quoin Pharmaceuticals, Ltd.
Purchase(P)Direct10.2K shares at avg. $4.88$50K - Feb 4, 2026QNRX
Quoin Pharmaceuticals, Ltd.
Award(A)DirectShare Option (Right to Buy)
85.3K shares- - Dec 1, 2025QNRX
Quoin Pharmaceuticals, Ltd.
Award(A)DirectShare Option (Right to Buy)
10.3K shares-
1-3 of 3 transactions
About Lawlor Sally Bridget
Lawlor Sally Bridget (SEC CIK 0002084407) files insider reports with the SEC as Chief Financial Officer of Quoin Pharmaceuticals, Ltd. (QNRX).
Signal8 holds 4 ownership filings by Lawlor Sally Bridget (1 Form 3, 3 Form 4), filed between Sep 8, 2025 and Sep 1, 2026. Those filings report 3 transactions, from Dec 1, 2025 to Aug 31, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Lawlor Sally Bridget's filings is in ASHBURN, VA.
Recent filings by Lawlor Sally Bridget
Other insiders filing for Quoin Pharmaceuticals, Ltd. (QNRX)
- LANGER DENNIS, Director
- Carter Denise P., Chief Operating Officer
- Myers Michael, Chief Executive Officer
- Culverwell Anthony James, Director
- Cooper Joseph Patrick, Director
- SEMBER MICHAEL T, Director